ALPHARETTA, Ga.--(BUSINESS WIRE)--Cartiva, Inc., a developer of innovative products for the treatment of cartilage injuries and osteoarthritis, today announced it has completed enrollment in the MOTION trial, an international, multi-center study of the Company’s Cartiva Synthetic Cartilage Implant (SCI). The results of the MOTION trial, which has enrolled 233 patients at 12 sites in Canada and the United Kingdom (UK), are intended to establish the basis for a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration (FDA).
